WFH NETWORK

Novo Nordisk announces FDA approves the Biologics License Application for ESPEROCT®

Novo Nordisk announces that the US Food and Drug Administration (FDA) has approved the Biologics License Application for turoctocog alfa pegol, N8-GP, (ESPEROCT)®, a recombinant extended half-life factor VIII clotting factor concentrate for the treatment of adults and children with hemophilia A. To read the full press release please click here.